1. IDF Diabetes Atlas. Sixth edition. 2014.
2. Маслова О.В, Сунцов Ю.И. Эпидемиология сахарного диабета и микрососудистых осложнений. Сахарный диабет. 2011; 3: 6–11.
3. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes. N Engl J Med 2008; 358: 580–91.
4. Ceriello A, Ihnat MA, Thorpe JE. The «metabolic memory»: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009; 94 (2): 410–5.
5. Фармакоэкономическое моделирование отдаленных результатов лечения сахарного диабета 2 типа. Под ред. И.И.Дедова. М., 2010.
6. Thornalley PJ, Babaei-Jadidi R, Al AH et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007; 50: 2164–70.
7. Manzetti S, Zhang J, Van der Spoel D. Review Thiamin function, metabolism, uptake, and transport. Biochemistry 2014; 53 (5): 821–35.
8. Балаболкин М.И., Клебанова Е.М., Креминская В.М. Лечение сахарного диабета и его осложнений. Руководство для врачей. М.: Медицина, 2005.
9. Tarallo S, Beltramo E, Berrone E, Porta M. Human pericyte-endothelial cell interactions in co-culture models mimicking the diabetic retinal microvascular environment. Acta Diabetol 2012 [Epub ahead of print].
10. Babaei-Jadidi R, Karachalias N, Ahmed N et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110–20.
11. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia 2010; 53: 1506–16.
12. Rabbani N, Alam SS, Riaz S et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: A randomised, double-blind placebo-controlled pilot study. Diabetologia 2009; 52: 208–12.
13. Bidasee KR, Zhang Y, Shao CH et al. Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes 2004; 53 (2): 463–73.
14. Candido R, Forbes JM, Thomas MC et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92 (7): 785–92.
15. Kass DA. Getting better without AGE: new insights into the diabetic heart. Circ Res 2003; 92 (7): 704–6.
16. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996; 93 (10): 1905–12.
17. Miyata T, Hori O, Zhang J et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGEbeta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 1996; 98 (5): 1088–94.
18. Simm A, Bartling B, Silber RE. RAGE: a new pleiotropic antagonistic gene? Ann N Y Acad Sci 2004; 1019: 228–31.
19. Al-Attas OS, Al-Daghri NM, Alfadda AA et al. J Blood thiamine and its phosphate esters as measured by high-performance liquid chromatography: levels and associations in diabetes mellitus patients with varying degrees of microalbuminuria. Endocrinol Invest 2012; 35 (11): 951–6.
20. Waheed P, Naveed AK, Ahmed TJ. Pa Thiamine deficiency and its correlation with dyslipidaemia in diabetics with microalbuminuria. Med Assoc 2013; 63 (3): 340–5.
21. Polizzi FC, Andican G, Çetin E et al. Increased DNA-glycation in type 2 diabetic patients: the effect of thiamine and pyridoxine therapy. Exp Clin Endocrinol Diabetes 2012; 120 (6): 329–34.
22. González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA et al. Eur Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naïve patients with type 2 diabetes. J Nutr 2011; 50 (2): 145–9.
23. Rabbani N, Alam SS, Riaz S et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia 2009; 52 (2): 208–12.
24. Al-Attas O, Al-Daghri N, Alokail M et al. Metabolic Benefits of Six-month Thiamine Supplementation in Patients With and Without Diabetes Mellitus Type 2. Clin Med Insights: Endocrinol & Diabetes 2014: p. 7.
25. Hellmann H, Mooney S Review Vitamin B6: a molecule for human health? Molecules 2010; 15 (1): 442–59.
26. Ahn HJ, Min KW, Cho YO. Assessment of vitamin B(6) status in Korean patients with newly diagnosed type 2 diabetes. Nutr Res Pract 201; 5 (1): 34–9.
27. Song Y, Cook NR, Albert CM et al. Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial. Diabetes 2009; 58 (8): 1921–8.
28. Unoki-Kubota H, Yamagishi S, Takeuchi M et al. Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett 2010; 17 (9): 1177–81.
29. Polizzi FC, Andican G, Çetin E et al. Increased DNA-glycation in type 2 diabetic patients: the effect of thiamine and pyridoxine therapy. Exp Clin Endocrinol Diabetes 2012; 120 (6): 329–34.
30. Smolek MK, Notaroberto NF, Jaramillo AG, Pradillo LR. Intervention with vitamins in patients with nonproliferative diabetic retinopathy: a pilot study. Clin Ophthalmol 2013; 7: 1451–8.
31. Degenhardt TP, Alderson NL, Arrington DD et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939–50.
32. Metz TO, Alderson NL, Chachich ME et al. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem 2003; 278: 42012–9.
33. O'Leary F, Samman S. Review Vitamin B12 in health and disease. Nutrients 2010; 2 (3): 299–316.
34. Al-Maskari MY, Waly MI, Ali A et al. Folate and vitamin B12 deficiency and hyperhomocysteinemia promote oxidative stress in adult type 2 diabetes. Nutrition 2012; 28 (7–8): e23–e26.
35. Ben Ahmed H, Bouzid K, Hassine M et al. Prevalence of non-conventional cardiovascular risk factors in Tunisian diabetics. Presse Med 2014; 43 (1): e9–e16.
36. Molina M, Gonzalez R, Folgado J et al. Correlation between plasma concentrations of homocysteine and diabetic polyneuropathy evaluated with the Semmes-Weinstein monofilament test in patients with type 2 diabetes mellitus. Med Clin (Barc.) 2013; 141 (9): 382–6.
37. Li J, Shi M, Zhang H et al. Relation of homocysteine to early nephropathy in patients with Type 2 diabetes. Clin Nephrol 2012; 77 (4): 305–10.
38. Jianbo L, Yuche C, Ming S et al. Association of homocysteine with peripheral neuropathy in Chinese patients with type 2 diabetes. Diabetes Res Clin Pract 2011; 93 (1): 38–42.
39. Ukinc K, Ersoz HO, Karahan C et al. Methyltetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy. Endocrine 2009; 36 (2): 255–61.
40. Satyanarayana A, Balakrishna N, Pitla S et al. Status of B-vitamins and homocysteine in diabetic retinopathy: association with vitamin-B12 deficiency and hyperhomocysteinemia. PLoS One 2011; 6 (11): e26747.
41. Ebesunun MO, Obajobi EO. Elevated plasma homocysteine in type 2 diabetes mellitus: a risk factor for cardiovascular diseases. Pan Afr Med J 2012; 12: 48.
42. Shargorodsky M, Boaz M, Pasternak S et al. Serum homocysteine, folate, vitamin B12 levels and arterial stiffness in diabetic patients: which of them is really important in atherogenesis? Diabetes Metab Res Rev 2009; 25 (1): 70–5.
43. Day C. ADA-EASD diabetes guidance: individualised treatment of hyperglycaemia. Br J Diabetes Vasc Dis 2012; 12: 146.
44. American Diabetes Association Position statement – Standards of Medical Care in Diabetes. Diabetes Care 2012, 35: S11–S63.
45. DeFronzo R, Goodman A. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541–9.
46. Pflipsen M, Oh R, Saguil A et al. The Prevalence of Vitamin B12 Deficiency in Patients with Type 2 Diabetes: A Cross-Sectional Study. J Am Board Fam Med 2009; 22: 528–34.
47. Hermann L, Nilsson B, Wettre S. Vitamin B12 status of patients treated with metformin: a cross-sectional cohort study. Br J Diabetes Vasc Dis 2004; 4: 401.
48. Nervo M, Lubini A, Raimundo F et al: Vitamin B12 in metformin-treated diabetic patients: a cross-sectional study in Brazil. Rev Assoc Med Bras 2011; 57: 46–9.
49. Liu K, Dai L, Jean W. Metformin-related vitamin B12 deficiency. Age Ageing 2006; 35: 200–1.
50. Bell D. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J 2010; 103: 265–7.
51. Kumthekar A, Gidwani H, Kumthekar A. Metformin Associated B12 Deficiency. J Assoc Physicians of India 2012; 60: 58–9.
52. Kos E, Liszek M, Emanuele M et al. Effect of metformin therapy on vitamin D and vitamin B12 levels in patients with type 2 diabetes mellitus. Endocr Pract 2012; 18: 179–84.
53. De-Jager J, Kooy A, Lehert P et al: Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010; 340: c2181.
54. Ting R, Szeto C, Chan M et al. Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin. Arch Intern Med 2006; 166: 1975–9.
55. Wulffele M, Kooy A, Lehert P et al: Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003; 254: 455–63.
56. Andre`s E, Noel E, Goichot B. Metformin-associated vitamin B12 deficiency. Arch Intern Med 2002; 162: 2251–2.
57. Bauman W, Shaw S, Jayatilleke E et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000; 23: 1227–31.
58. Токмакова А.Ю., Анциферов М.Б. Возможности использования Нейромультивита в комплексной терапии полинейропатии у больных сахарным диабетом. Сахарный диабет. 2001; 2 (7).
59. Удовиченко О.В. Эффективность Нейромультивита при диабетической полинейропатии. Новые лекарственные препараты. 2001; 2: 6–12.
60. Цагурия К.Г, Котешкова О.М., Савина Т.С. Нейромультивит в лечении диабетической периферической нейропатии. Новые лекарственные препараты. 2001; 2: 3–5.

В.И.Новиков, К.Ю.Новиков

ГБОУ ВПО Смоленский государственный медицинский университет Минздрава России